Trastuzumab emtansine (T-DM1) vs trastuzumab (H) in Chinese patients (pts) with residual invasive disease after neoadjuvant chemotherapy for HER2-positive breast cancer (BC) in the phase III KATHERINE study

被引：0
|
作者：
Huang, C. [1 ,2 ]
Yang, Y. [3 ,4 ]
Kwong, A. [5 ]
Chen, S-C. [6 ]
Tseng, L-M. [7 ]
Liu, M-C. [8 ]
Shen, K. [9 ]
Wang, S. [10 ]
Ng, T-Y. [11 ]
Feng, Y. [12 ]
Sun, G. [12 ]
Yan, I. R. [12 ]
Shao, Z. [13 ]
机构：
[1] Natl Taiwan Univ Hosp, Dept Surg, Taipei, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei, Taiwan
[3] China Med Univ, Taichung Vet Gen Hosp, Taipei, Taiwan
[4] China Med Univ, Sch Med, Taipei, Taiwan
[5] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Peoples R China
[6] Chang Gung Med Fdn, Div Gen Surg, Taipei, Taiwan
[7] Taipei Vet Gen Hosp, Dept Surg, Taipei, Taiwan
[8] Koo Fdn Sun Yat sen Canc Ctr, Oncol, Taipei, Taiwan
[9] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai, Peoples R China
[10] Sun Yat Sen Univ, Canc Ctr, Med Oncol, Guangdong Sheng, Peoples R China
[11] Tuen Mun Hosp, Clin Oncol, Hong Kong, Peoples R China
[12] Roche China Holding Ltd, PDO, Shanghai, Peoples R China
[13] Fudan Univ, Shanghai Canc Ctr, Breast Surg, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1O
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis
    Mano, Max S.
    Loibl, Sibylle
    Mamounas, Eleftherios P.
    von Minckwitz, Gunter
    Huang, Chiun-Sheng
    Untch, Michael
    Wolmark, Norman
    Wapnir, Irene L.
    Yang, Youngsen
    Conlin, Alison K.
    Kuemmel, Sherko
    Saghatchian, Mahasti
    DiGiovanna, Michael P.
    Strunk, Claudia
    Zimovjanova, Martina
    Song, Chunyan
    Liu, Haying
    Tesarowski, David
    Blotner, Steven
    Lam, Lisa H.
    Smitt, Melanie
    Geyer, Charles E., Jr.
    CANCER RESEARCH, 2020, 80 (04)
  • [2] Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
    Huang, Chiun-Sheng
    Yang, Youngsen
    Kwong, Ava
    Chen, Shin-Cheh
    Tseng, Ling-Ming
    Liu, Mei-Ching
    Shen, Kunwei
    Wang, Shusen
    Ng, Ting-Ying
    Feng, Yi
    Sun, Guofang
    Yan, Iris Renfei
    Shao, Zhimin
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 187 (03) : 759 - 768
  • [3] Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study
    Chiun-Sheng Huang
    Youngsen Yang
    Ava Kwong
    Shin-Cheh Chen
    Ling-Ming Tseng
    Mei-Ching Liu
    Kunwei Shen
    Shusen Wang
    Ting-Ying Ng
    Yi Feng
    Guofang Sun
    Iris Renfei Yan
    Zhimin Shao
    Breast Cancer Research and Treatment, 2021, 187 : 759 - 768
  • [4] Biomarker data from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
    Denkert, Carsten
    Lambertini, Chiara
    Fasching, Peter A.
    Pogue-Geile, Katherine L.
    Mano, Max S.
    Untch, Michael
    Wolmark, Norman
    Huang, Chiung-Sheng
    Loibl, Sibylle
    Mamounas, Eleftherios P.
    Von Minckwitz, Gunter
    Geyer, Charles E.
    Boulet, Thomas
    Song, Chunyan
    Phillips, Gail Lewis
    Nowicka, Malgorzata
    de Haas, Sanne
    Basik, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE
    Geyer, C. E., Jr.
    Huang, C-S
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Fischer, H. H.
    Redondo, A.
    Jackisch, C.
    Jacot, W.
    Conlin, A. K.
    Schneeweiss, A.
    Wapnir, I. L.
    Fasching, P. A.
    DiGiovanna, M. P.
    Wuelfing, P.
    Arce-Salinas, C.
    Crown, J. P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    von Minckwitz, G.
    CANCER RESEARCH, 2019, 79 (04)
  • [6] Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (T) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2+breast cancer: Subgroup analysis from KATHERINE
    Loibl, S.
    Huang, C-S.
    Mano, M. S.
    Mamounas, T. P.
    Geyer, C. E.
    Untch, M.
    von Minckwitz, G.
    Thery, J. -C.
    Schwaner, I.
    Limentani, S.
    Loman, N.
    Lubbe, K.
    Chang, J. C.
    Hatschek, T.
    Tesarowski, D.
    Boulet, T.
    Wiese, C.
    Song, C.
    Wolmark, N.
    ANNALS OF ONCOLOGY, 2020, 31 : S48 - S48
  • [7] Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer.
    Schneeweiss, Andreas
    Loibl, Sibylle
    Mamounas, Eleftherios P.
    von Minckwitz, Gunter
    Mano, Max S.
    Untch, Michael
    Huang, Chiun-Sheng
    Rastogi, Priya
    Conte, Pier Franco
    D'hondt, Veronique
    Redondo, Andres
    Stamatovic, Ljiljana
    Bonnefoi, Herve R.
    Castro Salguero, Hugo Raul
    Fischer, Hans Holger
    Wahl, Tanya A.
    Song, Chunyan
    Blotner, Steven
    Trask, Peter
    Geyer, Charles E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
    Boyraz, Baris
    Sendur, Mehmet A. N.
    Aksoy, Sercan
    Babacan, Taner
    Roach, Emir C.
    Kizilarslanoglu, Muhammet C.
    Petekkaya, Ibrahim
    Altundag, Kadri
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
  • [9] Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
    Denkert, Carsten
    Lambertini, Chiara
    Fasching, Peter A.
    Pogue-Geile, Katherine L.
    Mano, Max S.
    Untch, Michael
    Wolmark, Norman
    Huang, Chiun-Sheng
    Loibl, Sibylle
    Mamounas, Eleftherios P.
    Geyer Jr, Charles E.
    Lucas, Peter C.
    Boulet, Thomas
    Song, Chunyan
    Lewis, Gail D.
    Nowicka, Malgorzata
    de Haas, Sanne
    Basik, Mark
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1569 - 1581
  • [10] Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC)
    Untch, M.
    Geyer, C. E., Jr.
    Huang, C.
    Loibl, S.
    Wolmark, N.
    Mano, M. S.
    von Minckwitz, G.
    Brufsky, A.
    Pivot, X.
    Polikoff, J.
    Fontana, A.
    Kaufman, B.
    Alcedo, J. C.
    Boulet, T.
    Liu, H.
    Song, C.
    Mamounas, E. P.
    ANNALS OF ONCOLOGY, 2019, 30
12345